Zero tolerance for complacency by government of West African countries in the face of COVID-19.


Journal

Human antibodies
ISSN: 1875-869X
Titre abrégé: Hum Antibodies
Pays: Netherlands
ID NLM: 9711270

Informations de publication

Date de publication:
2021
Historique:
pubmed: 18 5 2020
medline: 24 4 2021
entrez: 18 5 2020
Statut: ppublish

Résumé

A novel Coronavirus (SARS-CoV-2) causing a cluster of respiratory infections (Coronavirus Disease 2019, COVID-19) first discovered in Wuhan, China, is responsible for a new illness that has been found to affect the lungs and airways of patients with associated symptoms of fever, cough and shortness of breath. In the light of few cases recorded so far in West Africa there is tendency for complacency. The region needs to make strategic plans based on available evidence to enable them effectively deal with this rapidly evolving pandemic. At this very moment countries like China, Italy, France, Spain, Iran, UK and many others are witnessing sustained and intensive community transmission of this virus and increasing numbers of severe disease and death particularly among elderly patients with other comorbidities. The reality of the seriousness of this pandemic is alarming. Government of member states of ECOWAS need to prepare themselves by building capacity as well as implement evidenced-based steps to mitigate this rapidly evolving pandemic by testing persons presenting with symptoms (fever, cough and shortness of breath), isolating and treating those found positive, tracing and quarantining contacts, implementing social distancing as well as optimizing human and material endowment to allow healthcare workers offer safe quality clinical care for affected patients to prevent secondary infection among healthcare workers.

Identifiants

pubmed: 32417768
pii: HAB200413
doi: 10.3233/HAB-200413
pmc: PMC8150474
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-40

Références

BMJ. 2014 Sep 04;349:g5485
pubmed: 25193934
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Travel Med Infect Dis. 2014 Sep-Oct;12(5):541-2
pubmed: 25219797
J R Soc Med. 2014 Jun 9;107(1 suppl):46-54
pubmed: 24914128
Biosecur Bioterror. 2013 Jun;11(2):153-6
pubmed: 23745521
One Health. 2019 Jan 09;7:100080
pubmed: 30671528
Nat Med. 2006 May;12(5):497-9
pubmed: 16675989
Clin Med (Lond). 2015 Oct;15(5):457-60
pubmed: 26430185
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186
Trop Doct. 2015 Jan;45(1):2-5
pubmed: 25527679
BMC Health Serv Res. 2006 Oct 19;6:135
pubmed: 17052326
Nature. 2008 Feb 21;451(7181):990-3
pubmed: 18288193
Curr Infect Dis Rep. 2015 May;17(5):480
pubmed: 25896751
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Emerg Infect Dis. 2003 Jun;9(6):718-20
pubmed: 12781013
Lancet. 2014 Oct 11;384(9951):e49-51
pubmed: 25201591
PLoS One. 2011 Jan 19;6(1):e16094
pubmed: 21283514
Front Public Health. 2015 Jul 01;3:166
pubmed: 26191520
Clin Infect Dis. 2002 Nov 1;35(9):1071-2
pubmed: 12398064
Lancet Infect Dis. 2008 Oct;8(10):650-8
pubmed: 18922487
Front Health Serv Manage. 1994 Fall;11(1):50-2
pubmed: 10136978
Emerg Infect Dis. 2016 Feb;22(2):350-2
pubmed: 26812203
Lancet Glob Health. 2015 Feb;3(2):e71-2
pubmed: 25617195
Global Health. 2011 Jul 04;7:21
pubmed: 21726434
J Transl Med. 2015 Jan 16;13:11
pubmed: 25592846
Int Arch Med. 2008 Dec 18;1(1):27
pubmed: 19094201
Glob Public Health. 2016 Mar;11(3):253-275
pubmed: 25642809
MMWR Suppl. 2016 Jul 08;65(3):57-67
pubmed: 27390092
MMWR Morb Mortal Wkly Rep. 2014 Oct 3;63(39):867-72
pubmed: 25275332
Emerg Med J. 2015 Jul;32(7):571-3
pubmed: 26045442
Educ Health (Abingdon). 2006 Nov;19(3):385-7
pubmed: 17178522
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7588-93
pubmed: 17416677
Can J Public Health. 2005 Jan-Feb;96(1):52-4
pubmed: 15682697
Emerg Infect Dis. 2009 Jun;15(6):e1
pubmed: 21970033
J Infect Dis. 2016 May 1;213 Suppl 3:S116-23
pubmed: 26912379
Lancet. 2003 May 3;361(9368):1519-20
pubmed: 12737864
Nurs Outlook. 2015 Jan-Feb;63(1):30-40
pubmed: 25645480
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Health Res Policy Syst. 2017 Jul 12;15(Suppl 1):55
pubmed: 28722555
J Infect Dev Ctries. 2014 Nov 13;8(11):1378-80
pubmed: 25390049
Soc Sci Med. 2003 Nov;57(10):1957-67
pubmed: 14499518
Global Health. 2017 Jan 4;13(1):1
pubmed: 28049495
Lancet. 2015 Nov 28;386(10009):2204-21
pubmed: 26615326
Mayo Clin Proc. 2014 Dec;89(12):1596-8
pubmed: 25467643
PLoS Med. 2006 Jun;3(6):e271
pubmed: 16719557

Auteurs

O Erhabor (O)

Department of Haematology, SMLS, Usmanu Danfodiyo University, Sokoto, Nigeria.

T Erhabor (T)

Medical Laboratory Science Council of Nigeria, Nigeria.

T C Adias (TC)

Federal University Otuoke Bayelsa State, Nigeria.

G C Okara (GC)

West African Postgraduate College of Medical Laboratory Science, Nigeria.

M Retsky (M)

Harvard School of Public Health, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH